Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.

被引：0
|
作者：
Strati, Paolo
Leslie, Lori Ann
Shiraz, Parveen
Budde, L. Elizabeth
Oluwole, Olalekan O.
Ulrickson, Matthew
Ramakrishnan, Aravind
Sun, Jennifer
Shen, Rhine
Kanska, Justyna
McCroskery, Peter
Dong, Jinghui
Schupp, Marco Andreas
Xu, Hairong
Patel, Krish
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[2] John Theurer Canc Ctr, Hackensack, NJ USA
[3] Stanford Univ, Stanford, CA USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Texas Transplant Physician Grp, Austin, TX USA
[8] Gilead Co, Kite, Santa Monica, CA USA
[9] Swedish Canc Inst, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7567
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
    Logue, Jennifer Marilyn
    Krivenko, Gabriel S.
    Larson, Victoria
    Bachmeier, Christina A.
    Chavez, Julio C.
    Davila, Marco L.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien D.
    Pinilla-Ibarz, Javier
    Shah, Bijal D.
    Dholaria, Bhagirathbhai R.
    Jain, Michael D.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
    Diakite, I
    Lin, V. W.
    Klijn, S.
    Navale, L.
    Purdum, A. G.
    Fenwick, E.
    Botteman, M.
    van Hout, B.
    VALUE IN HEALTH, 2019, 22 : S41 - S41
  • [3] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
    Hathway, Joanne
    Purdum, Anna
    Lin, Vincent W.
    Cyr, Philip
    Westin, Jason
    Jensen, Ivar
    BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
  • [4] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
    Neelapu, Sattva Swarup
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David Bernard
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianqing
    Rossi, John M.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick
    Bartlett, Nancy
    Jacobson, Caron
    Oluwole, Olalekan
    Munoz, Javier
    Lekakis, Lazaros
    Topp, Max
    Avivi, Irit
    Kim, Jenny
    Chu, Rong
    Zheng, Lianqing
    Rossi, John
    Bot, Adrian
    Neelapu, Sattva
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
  • [6] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
    Lin, Vincent W.
    Jiang, Yizhou
    Chuang, Ling Hsiang
    Navale, Lynn
    Cheng, Paul
    Purdum, Anna
    BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879
  • [7] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Jacobson, C. A.
    Oluwole, O. O.
    Munoz, J.
    Lekakis, L. J.
    Topp, M. S.
    Avivi, I
    Kim, J. J.
    Chu, R.
    Zheng, L.
    Rossi, J. M.
    Bot, A.
    Neelapu, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
  • [8] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Houot, Roch
    Minnema, Monique
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
  • [9] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
    Locke, Frederick L.
    Siddiqi, Tanya
    Jacobson, Caron Alyce
    Ghobadi, Armin
    Ahmed, Sairah
    Miklos, David Bernard
    Perales, Miguel-Angel
    Munoz, Javier
    Logan, Brent
    Hu, Zhen-Huan
    Miao, Harry H.
    Singh, Kanwarjit
    Shah, Jina
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345